Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...